The state of CRC
- CRC by the numbers
- The adherence problem
The Shield™ blood test
- An easier way to screen
- Clinical results
Legacy of innovation
Coverage and support
- Medicare coverage
- Guardant support
Seamless integration
Resources
- FAQs

Request info

Patients

NOW FDA APPROVED FOR COLORECTAL CANCER (CRC) SCREENING

Why screen for colon cancer with Shield?

EXPLORE

Shield Portal
Corporate Website
Guardant Complete

INFORMATION

Annual Notice
Provider Brochure
Patient Fact Sheet
Shield Instructions for Use
Blood Collection Kit Information

3100 Hanover Street
Palo Alto, CA 94304

1.855.722.7335

Privacy Policy/ Terms/ Notice of Privacy Practices

In the event the test is not fully covered by insurance, the Shield IVD test will be available for a cash pay rate of $1,495 effective on August 1, 2024, the first day the test is commercially available.

Additional data²

13^%

sensitivity for advanced adenomas

23^%

sensitivity for high-grade dysplasia

99.9^%

negative predictive value^*

^* The probability that a negative test result is truly negative.⁶

Sensitivity based on stage at diagnosis^7†

^†Excludes 2 CRC stage unknown (1/2 detected)

^‡Assumes 5 incompletely staged by AJCC malignant polyps are Stage 1 disease

AJCC=American Joint Committee on Cancer.

Thanks to Shield™, you can help improve colorectal cancer screening adherence

Want to learn more about the Shield blood test? Complete the form below to stay up to date

*Required fields

I am interested in ordering Shield (Optional)

Phone number * (Format: 101-555-1212)

Email address *

First name *

Last name *

Specialty *

NPI# (Optional)

Organization *

Employer *

ZIP code *

Questions or comments? (Optional)

* Required fields

By submitting your information, you agree to our Privacy Policy and agree to receive periodic product-related updates via email from Guardant Health.

By clicking “Submit” you certify that you are a U.S. healthcare provider.

By providing your information, you consent to receiving marketing and promotional communications and other information from Guardant Health. You hereby give consent to Guardant, its affiliates, and their agents and representatives to send communications and information to you via the contact information you have provided above. You agree to our privacy policy and may opt out via the link within our communications.

Thank you!

We’ve received your information. A Shield team member will be reaching out to you in the next 24-48 business hours to address your questions.

Please check your inbox for an email with helpful information in the meantime.

We’ve received your information, and your first email is on its way to help address any questions. Be sure to check your inbox for regular updates from Shield.

Fill out the form to find out more about how you can help facilitate earlier CRC screening among your employees

You can also email us directly at GetScreened@GuardantHealth.com

*Required fields

First name*

Last name*

Company name*

Title*

Phone number*

Email address*

Are you interested in (select up to 3):

On-site clinic implementation and screening

On-site screening event

Education materials

Thank you!

We’ve received your information. A dedicated account director will be reaching out to you personally to ensure that all your questions are answered.

We look forward to working with you!

Why screen for colon cancer with Shield?

13%

23%

99.9%

13^%

23^%

99.9^%